Pharmacoeconomic Study of First-Line Perindopril/Indapamide Combination in Lowering Blood Pressure and Reducing Albuminuria

Author: Ambrosioni, Ettore

Source: High Blood Pressure & Cardiovascular Prevention, Volume 12, Number 4, 2005 , pp. 203-213(11)

Buy & download fulltext article:

Price: $62.95 plus tax (Refund Policy)

Abstract:

Aim: The aim of this study was to provide a pharmacoeconomic profile of Preterax^® (perindopril/indapamide) [Servier, France] based on the application of validated analytical methodologies to recently published clinical trial results.

Method: Pharmacoeconomic models were applied to studies comparing perindopril/indapamide with losartan and irbesartan in essential hypertension, and with enalapril in hypertensive diabetic patients with albuminuria. The daily cost savings per 1mm Hg reduction in blood pressure (BP) associated with reduced need for dialysis were calculated. The analyses were adapted for Germany, France and Italy, based on drug acquisition costs in euro at December 2002. The costs of end-stage renal disease were calculated at October 2002 prices in euro, based on January 1991 prices in deutschmark adjusted for inflation and exchange rate.

Results: The cost of BP normalisation with perindopril/indapamide was compared with losartan and irbesartan in two studies. The cost of BP normalisation with perindopril/indapamide was 27.83% less than that with losartan in Germany, 14.97% less in France and 30.36% less in Italy. The cost of BP normalisation with perindopril/indapamide was 41.40% less than that with irbesartan in Germany, 53.73% less in France and 30.36% less in Italy.

Discussion: Perindopril/indapamide costs less per patient per year than losartan and irbesartan to normalise BP, increase life expectancy, and prevent cardiovascular and cerebrovascular disease. In comparison with enalapril, perindopril/indapamide ensured greater overall treatment savings despite a drug acquisition cost in favour of enalapril.

Conclusion: Perindopril/indapamide should be considered for first-line treatment of essential hypertension and of albuminuria in patients with type 2 diabetes mellitus.

Keywords: Cost effectiveness; Enalapril; Essential hypertension; Irbesartan; Losartan; Perindopril/indapamide; Pharmacoeconomics; Proteinuria

Document Type: Research article

Affiliations: 1: University of Bologna, Bologna, Italy

Publication date: 2005-01-01

Pharmacoeconomic Study of First-Line Perindopril/Indapamide Combination in Lowering Blood Pressure and Reducing Albuminuria

Buy & download fulltext article:

Tools

Key

Text size:

Useful pages